Multiple common tumor-associated antigens (Multi-TAA)

"Multiple common tumor-associated antigens" (Multi-TAA) refers to a strategic target profile used in multi-antigen-specific T-cell therapies and polyvalent cancer vaccines. These antigens—such as PRAME, WT1, Survivin, NY-ESO-1, and MAGE-A4—are non-mutated proteins that are overexpressed or aberrantly expressed in tumors compared to healthy tissues [7, 15]. By targeting multiple antigens simultaneously, these therapies aim to overcome tumor heterogeneity and the risk of "antigen escape," a process where cancer cells evade single-target therapies (like CAR-T or monoclonal antibodies) by downregulating a specific target [3, 10]. This collective targeting approach is a hallmark of non-genetically modified T-cell products like MT-601, which expand endogenous T-cell populations to provide a broader anti-tumor response [6, 7]. Clinically, this multi-target method has demonstrated a favorable safety profile with lower risks of severe cytokine release syndrome and neurotoxicity compared to single-antigen engineered therapies [3, 12]. Although the term describes a collection of targets rather than a single molecule, it is the designated functional target for several next-generation immunotherapies currently in clinical trials for hematological and solid malignancies [7, 17].

Other names

Multi-TAAsTumor-associated antigensTAAMulti-antigen recognizing T cellsMAR T cellsShared tumor antigens

Induction and expansion of non-genetically modified, polyclonal T cells that recognize multiple tumor-associated epitopes simultaneously to provide broad anti-tumor activity and minimize antigen escape [3, 6].